Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002813 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00002813: Completed Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT00002813 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 62 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002813, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with cisplatin and vinorelbine in treating patients with refractory or recurrent squamous cell cervical cancer that has not responded to local therapy.
Interventions
- DRUG cisplatin
- DRUG vinorelbine tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 1997-08 |
| Phase | Phase 2 |
What the finished NCT00002813 record still lists
NCT00002813 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.
NCT00002813 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002813 about?
NCT00002813 is a clinical study titled "Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with cisplatin and vinorelbine in treating p...
What is the current status of trial NCT00002813?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 1997-08.
What interventions are being tested in trial NCT00002813?
The interventions under investigation include: cisplatin (DRUG), vinorelbine tartrate (DRUG).
Who is sponsoring clinical trial NCT00002813?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002813's enrollment target sits among peer trials
62 1016th of 2000 higher than 975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia